Ceftazidime, a new parenteral broad spectrum cephalosporin, is stable to most 6-lactamases and has high activity against Pseudomonas species, Providencia, Serratia and indole positive Proteus. Studies in adult human volunteers demonstrate high long lasting serum levels, low serum binding and high recovery of unchanged antibiotic in the urine, and have failed to reveal any evidence of toxicity. Sixteen newborn infants received treatment with intravenous Ceftazidime 30 mg/kg 12 hourly for suspected neonatal sepsis. The median gestational age of the infants was 32 weeks (range 26-42 weeks) and the mean birthweight 1700 grams (range 820-3520 grams). Pharmacokinetics of Ceftazidime were determined in the infants and serum concentration time curves were characterised by the two compartment open system kinetic model. The mean serum concentration 1 hour after the 30 mg/kg infusion was 38.95 mg/L and the mean serum trough level was 13.8 mg/L. Elimination half-lives correlated inversely with gestational age. The mean half lives during the first week of life were 5.0 hours in infants <32 weeks, 4.7 hours in those 32-37 weeks, and 3.3 hours in term infants. The drug was well tolerated and adverse effects were not observed. This study examinez whether "erapamil (V) can block a adrenoceptors in newborns, as reported i n adults (Bou, J. et al., & hi^^ Pharmac. 3: 219-232, 1983). CV responses to the a agonist, phenylephrine (PE), given as an i.v. bolus (20 mcg/kg)l were examined before and immediately after a 2 min i.v. infusion of 100 or 300 mcg/kg V in 28 anesthetized, 1 day and 2 week old piglets. ECG, heart rate (HR), aortic (AoP) and LV pressures, LV dP/dt max and phasic mesenteric (Mes), renal (Ren) and femoral (Fem) flows were recorded;..vascular resistance (R) was calculated. PE increased mean AoP, MesR and RenR and decreased HR with no consistent changes in LV dP/dt max and FemR. In 1 day olds, there was no significant difference in CV responses to PE before and after V. In 2 week olds after high dose V, the following responses (mean % change A SE) to PE were significantly diminished: MesR (174d8 vs 85S3; pL0.02), RenR (246241 vs 124229; pL0.02), mean AoP (5426 vs 3 8~5 ; pL0.003). The smaller increase in mean AoP elicited less of a reflex bradycardia After low dose V the PE induced increase in LV dP/dt max was augmented (1h4 vs 2 2~4 ; p<0.04), while the increase in RenR to PE was diminished in all 2 week olds. The results indicate that the ability of V to block a adrenoceptors matures postnatally. This may be another manihestation of functional immaturity of a adrenoceptors at birth. The results of the present study provide a basis for understanding the age-and dosedependent CV effects of V observed in young swine (Gootman, N. et al, Pediatr, I k 3~ 18: 122A, 1984).
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The majority of infants born to drug-pendent women undergo neonatal abstinence syndrane (NAS) and often require pharmwotherapy for the treatxent of with-&-anal symptons. Phenobarbital, paregoric, and diazepam have been r e c m d e d for the treatment of the syndrane. While sane investigators have exmined the efficacy of these agents in treating NAS, there are no data regark the use of specific phannacologic agents and developnental outcane. This study evaluated 85 infants born to drug-dependent wmen who were maintained on methadone during mgnancy. Severity of infant withdram2 was assessed with the Neonatal Abstinence Scoring systan (Pediatric Research 7: 319, 1973) . Infants who required phamacotherapy were randanly assigned to one of four treatment regimens: paregoric, phenobarbitol (titration), phenobarbitol (loading), and diazepam. When treatxent was not successful with the assigned agent, one of the other agent(s) was used. At 6 months of age, the developnental status of infants was assessed with the Bayley Scales of Mental &velopent. Based on NAS treatment, four groups were delineated: I) paregoric (n=2l); 11) phenobarbitol (n=17); 111) more than one agent (n=31); and N ) no treatxent. (Data for the phenobarbitol loading and titration groups were cmbined since analysis revealed no differences between groups. All infants who initialLv received diazepm were included in Group I11 since diazepam as a single agent was not successful). Results of one way analysis of variance revealed no differences in developnental status between groups (p = c.10, f=.25). Scores for all groups were well within the normal range of development. Jmplications of these findings include, 1) the severity of withdram2 is not related to developnental outcane when appropriately managed with pharmacotherapy, and 2) the use of pharmacotherapy does not adversely effect the developmental outcane and may help meloriate the consequences of NAS. Methotrexate (MTX) a mainstay o f c o n t i n u a t i o n therapy f o r a c u t e lymphoblastic leukemia i s associated w i t h hepatio and neurotoxic i t y . The metabolism o f MTX t o polyglutamates (MTXGLUn), which have l o n g i n t r a c e l l u l a r h a l f l i v e s may be p a r t i a l l y responsible f o r these t o x i c i t i e s . I n an e f f o r t t o m d e l t h e pharmacodynamics o f r e p e t i t i v e , low dose MTX and t h e f o l a t e d e f i c i e n c y p r e v i o u s l y shown i n r e d c e l l s and l i v e r s from p a t i e n t s , t h e t i s s u e content2 of MTX and f o l a t e from monkeys t r e a t e d f o r 1 y r w i t h 50 mgMTX/m was analyzed. I n a d d i t i o n , t h e MTXGLUn p r o f i l e s were also determined by HPLC and r a d i o l i g a n d b i n d i n g assay. The MTX content (pmol/g wet weight) o f l i v e r , kidney, brain, t e s t e s were 2817,836 4.9 and 44 r e s p e c t i v e l y . The f o l a t e content (pmollg wet weight) o f these same t i s s u e s was 11500, 4485, 32 and 
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474. Control values f o r f o l a t e s were 31064, 6500, 286 and 1355 r e s p e c t i v e l y . The predominant MTX d e r i v a t i v e ( s ) found were MTXGLU3-5 b u t GLU6-7 were e a s i l y detectable. Of special i n t e r e s t was t h e s i g n i f i c a n t f o l a t e d e f i c i e n c y found i n t h e b r a i n (90% l o s s compared t o c o n t r o l ) . Since inborn e r r o r s o f f o l a t e metabolism o f t e n present w i t h severe neurological problems n o t u n l i k e those associated w i t h MTX t o x i c i t y ( i n c l u d i n g cerebral c a l c i f i c a t i o n s ) , t h e biochemical abn o r m a l i t i e s associated w i t h r e p e t
i t i v e , low dose MTX therapy and i t s attendant f o l a t e d e f i c i e n c y may be responsible f o r t h e observed t o x i c i t y .
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DISPOSITION OF THEOPHYLLINE AN0 CAFFEINE
D e~t . o f Pharmaceutics and P e d i a t r i c s . L i t t l e Rock. A p h a r i a c o k i n e t i c (PK) studv t o evaluate t h e o i i l e t as a model f o r t h e o p h y l l i n e (T) a n d ' c a f f e j n e (C) d i s p o s i t i o n was undertaken
i n 28 animals who received a 10 mg/kg IV bolus i n j e c t i o n o f C o r T, followed by m u l t i p l e blood sampling over 24 hours. C and T were q u a n t i t a t e d from serum by HPLC (CV<3% a t 0.1-100 mg/L).
Comparison of T and C d i s p o s i t i o n was performed a t 2 (n=6 per group), 4-5 (n-4 per group) and 19-20 (n=4 per group) days o f age, and r e s u l t e d i n t h e f o l l o w i n g data (mean):
_ o f T clearance (CL) between t h e 4.25 and 20.25 day groups, and Vdarea f o r a l l age groups, there were s i g n i f i c a n t (p<0.05) d i f f e r e n c e s f o r C and T PK parameters between a l l age groups. C was n o t detectable i n p i g l e t s r e c e i v i n g T; however, T was detected (0.4k0.2 mg/L a t 11.5k4.2 h r ) i n t h e 4 o l d e s t p i gl e t s r e c e i v i n g C. PK parameters f o r C and T i n p i g l e t s studied a t 2 days o f age were s i m i l a r t o those reported i n human neonates. I n t h e o l d e r animals, they were markedly d i f f e r e n t than values reported f o r human neonates o f s i m i l a r age. Furthermore, a b i l i t y f o r T biotransformation t o C appears d e f i c i e n t i n t h e p i g l e t . These d i f f e r e n c e s from human neonates w i l l r e q u i r e f u r t h e r e l u c i d a t i o n f o r p i g l e t s t o be e f f e c t i v e "models". Studies of pharmacologic doses of vitamin E in our laboratory have shown that dosage form and route of administration influence the level and predominant form of vitamin E present in tissue. The functional significance of the quantity and predominant form of vitamin E in tissue was assessed by measurements of antioxidant activity in lung tissue resulting from IV administration of T or TA. One-day-old rabbits were given 0, 1, 10 and 100 %/kg T or TA IV. The lungs were removed, and a portion was saved for later HPLC analysis of vitamin E content. The remaining lung was homogenized and incubated with an ~elascorbate system to generate lipid peroxidation (LP). After 30 min, the reaction was stopped with EDTA; and LP was quantitated using a TBAbased method which measures malonaldehyde (MDA). Increasing IV doses of T resulted in increasing T levels in lung and a comparable lowering of LP (Dose:l mglkg, T level 19 + 5 mcg/g, MDA 203 + 38 nmoles/g; Dose: 100 %/kg, T level 1901+ 572 mcg/g, MDA 52 + 24 nrnoledg). TA given IV increased lung TA-levels, but no reduction in LP was observed (~ose:l mg/kg, TA level 90 + 68 mcg/g, MDA 297 + 122 nmoles/g; Dose:100 mglkg, TA levT1 1140 + 548 mcg/g, MDA 2Tl + 139 nmoles/g).
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In a defined in vitro oxidant stress sytem, T elicits a doserelated antioxidant effect. TA administration increased lung TA content but did not result in a significant reduction in LP. TA given IV appears to lack efficacy as an antioxidant in the lung.
